Berberine vs Retatrutide for appetite
Short answer: For appetite, more users report improvement with Berberine — 87% of 15 reports, versus 73% of 84 for Retatrutide.
Berberine has 109 meta-analyses and 110 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 294 reports about Berberine and 446 about Retatrutide. Not medical advice.
| Berberine Supplement | Retatrutide Peptide | |
|---|---|---|
| User score | 47 | 71 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 56% | 76% |
| Reports | 294 | 446 |
| Research | AResearch: Strong | BResearch: Moderate |
| Meta-analyses / RCTs | 109 / 110 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 84% (19) | 91% (222) |
| Appetite % reporting improvement | 87% (15) | 73% (84) |
| Focus % reporting improvement | 33% (6) | 83% (6) |
| Energy % reporting improvement | 90% (21) | 69% (75) |
| Sleep % reporting improvement | 75% (4) | 31% (26) |
| Anxiety % reporting improvement | 50% (8) | 40% (5) |
| Mood % reporting improvement | 86% (14) | 66% (32) |
| Performance % reporting improvement | 67% (3) | 82% (33) |
| Recovery % reporting improvement | — | 100% (8) |
| Pain & inflammation % reporting improvement | 100% (4) | 78% (9) |
| Digestion % reporting improvement | 60% (15) | 46% (13) |
| Libido % reporting improvement | — | 25% (12) |
| Hormones % reporting improvement | 67% (3) | 100% (13) |
| Blood sugar % reporting improvement | 86% (58) | 75% (4) |
| Heart & lipids % reporting improvement | 92% (13) | 37% (19) |
| Longevity % reporting improvement | 50% (2) | — |
| Common side effects | stomach issues, fatigue, constipation, anxiety | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | 400-500 mg / daily | Not listed |
Treatment with berberine may be safe since it does not increase the incidence of total adverse events and the risk of hypoglycemia. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=292975, identifier CRD42021292975.
Front Pharmacol, 2022 ↗“I started berberine and inositol, and began having energy that I did not have before. Somehow, my recovery after working out wasn't as long either.”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate